Login / Signup

The prevalence of post-NDA drug patents and their relationship to the timing of generic approval.

Jonathan J DarrowVictor Van de WieleBeatrice BrownAaron S Kesselheim
Published in: Nature biotechnology (2024)
Keyphrases
  • risk factors
  • drug administration
  • adverse drug